Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain

Social Psychiatry and Psychiatric Epidemiology

Volumn 48, Issue 6, 2013, Pages 985-996

  De Salas Cansado, Marina ^a   Álvarez, Enrique ^b   Olivares, José M ^c   Carrasco, Jose L ^d   Ferro, M Belén ^e   Rejas, Javier ^e  

^a Trial Form Support Spain   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e PFIZER INC   (United States)

Author keywords

Cost effectiveness; Generalised anxiety disorder; Pregabalin; QALYs; Refractory patients; Usual care

Indexed keywords

4 AMINOBUTYRIC ACID; ANXIOLYTIC AGENT; DRUG DERIVATIVE; PREGABALIN;

ANXIETY DISORDER; ARTICLE; CASE CONTROL STUDY; COST BENEFIT ANALYSIS; DOSE RESPONSE; ECONOMICS; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; SPAIN; STATISTICS; TREATMENT OUTCOME; UTILIZATION REVIEW;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SPAIN; TREATMENT OUTCOME;

EID: 84878620150     PISSN: 09337954     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00127-012-0606-6     Document Type: Article

References (46)

1. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J (2002) Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63(Suppl 8):24-34
2. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H et al (2004) Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 420:21-27
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602
4. Caballero L, Bobes J, Vilardaga I, Rejas J (2009) Clinical prevalence and reason for visit of patients with generalized anxiety disorder seen in the psychiatry out-patient clinics in Spain. Results of the LIGANDO study. Actas Esp Psiquiatr 37:17-20
5. Chocron Bentata L, Vilalta Franch J, Legazpi Rodriguez I, Auquer K, Franch L (1995) Prevalence of psychopathology at a primary care center. Aten Primaria 16:586-590
6. Katon W, Von Korff M, Lin E, Lipscomb P, Russo J, Wagner E, Polk E (1990) Distressed high utilizers of medical care: DMS-III-R diagnoses and treatment needs. Gen Hosp Psychiatr 12:355-362
7. Kennedy BL, Schwab JJ (1997) Utilization of medical specialists by anxiety disorder patients. Psychosomatics. 38:109-112
8. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disoders, Zohar J, Hollander E, Kasper S, Möller HJ, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lépine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 9:248-312
9. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Marshall RD, Nemeroff CB, Shalev AY, Yehuda R (2001) Consensus statement of generalized anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 62(Suppl. 11):53-58
10. Yonkers K, Warshaw M, Massion A, Keller M (1996) Phenomenology and course of generalised anxiety disorder. Br J Psychiatry 168:308-313
11. Kessler RC, Wittchen HU (2002) Patterns and correlates of generalized anxiety disorder in community samples. J Clin Psychiatry 63(Suppl. 8):4-10
12. Katzman MA (2009) Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 23:103-120
13. McLaughlin TP, Khandker RK, Kruzikas DT, Tummala R (2006) Overlap of anxiety and depression in a managed care population: prevalence and association with resource utilization. J Clin Psychiatry 67:1187-1193
14. Andlin-Sobocki P, Wittchen HU (2005) Cost of anxiety disorders in Europe. Eur J Neurol 12(Suppl. 1):39-44
15. Wittchen HU (2002) Generalized anxiety disorder: prevalence, burden, and cost to society. Depression Anxiety 16:162-171
16. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN (1996) The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 271:5768-5776
17. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Göthert M (2002) Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42:229-236
18. Dooley DJ, Donovan CM, Pugsley TA (2000) Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 295:1086-1093
19. Maneuf YP, Hughes J, McKnight AT (2001) Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain 93:91-96
20. Álvarez E, Carrasco JL, Olivares JM, Perez M, López- Gómez V, Vilardaga I, Rejas J (2010) Broadening of generalized anxiety disorders definition does not affect the response to therapy: findings from the ADAN study. Eur Psychiatr 25(Suppl 1):Abstract PW01-50
21. The American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. Text revision: DSM-IV-TR, paper. American Psychiatric Association, Washington, DC. ISBN 0-89042-025-4
22. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychiatry 32:50-55
23. Lobo A, Chamorro L, Luque A, Dal-Ré R, Badía X, Baró E (2002) Validación de las versiones en español de la Montgomery-Asberg Depression Scale y la Hamilton Anxiety Rating Scale para la evaluación de la depresión y de la ansiedad. Med Clin (Barc) 118:493-499
24. CGI (1976) In: Guy W (ed) ECDEU assessment manual for psycopharmacology revised. US Department of Health Education, and Welfare, NIH, Psycopharmacology Research Branch, Rockville, pp 218-222
25. EuroQoL Group (1990) EuroQoL - a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
26. Badía X, Roset M, Montserrat S, Herdman M, Segura A (1999) The Spanish version of EuroQoL: a description and its applications. European Quality of Life scale. Med Clin (Barc) 112(Suppl 1):79-85
27. Akehurst R (2002) In Towse A, Pritchard C, Devlin N (eds) Cost effectiveness thresholds: economic and ethical issues. London Kings Fund and Office of Health Economics, p 38
28. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL (2002) ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit 4:334-343
29. Rawlins MD, Culyer AJ (2004) National Institute for Clinical Excellence and its value judgments. BMJ 329:224-227
30. Culyer AJ (2002) Introduction. In: Towse A, Pritchard C, Devlin N (eds) Cost effectiveness thresholds: economic and ethical issues. London Kings Fund and Office of Health Economics pp 9-15
31. Catálogo del Consejo General de Colegios Farmacéuticos de España (2008)
32. Oblikue (2008) eSALUD. Base de datos de costes sanitarios. In: Social, S.C.d.E.e.E.d.l.S.y.P. (ed) SOIKOS, Barcelona
33. Brooks R (1996) EuroQoL: the current state of play. Health Policy 37:53-72
34. Revicki D, Brandenburg M, Matza LS, Morlock R, Hornbrook MC, Feeny D, Clarke G (2006) Relationship between anxiety severity and health utility index scores in generalized anxiety disorder. Collegium of Internationale Neuro-Psycharmacologicum (CINP), Chicago, 9-13 July
35. Morlock R, Shah H, Feltner D, Brandenburg N, Matza LS, Revicki D (2006) Estimation of health-state utilities for patients with generalized anxiety disorder. Collegium of Internationale Neuro-Psycharmacologicum (CINP), Chicago, 9-13 July
36. Bastida JL, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, Puig-Junoy J (2010) A proposed guideline for economic evaluation of health technologies. Gac Sanit 24:154-170
37. Heuzenröeder L, Donnelly M, Haby MM, Mihalopoulos C, Rossell R, Carter R, Andrews G, Vos T (2004) Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Psychiatry 38:602-612
38. Issakidis C, Sanderson K, Corry J, Andrews G, Lapsley H (2004) Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. Psychol Med 34:19-35
39. Guest JF, Russ J, Lenox-Smith A (2005) Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalized anxiety disorder in the United Kingdom. Eur J Health Econ 6:136-145
40. Jörgensen TR, Stein DJ, Despiegel N, Drost PB, Hemels ME, Baldwin DS (2006) Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Ann Pharmacother 40:1752-1758
41. Konnopka A, Leichsenring F, Leibing E, König HH (2009) Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect Disord 114:14-31
42. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, ISPOR Task Force on Good Research Practices - Modeling Studies (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices - modeling studies. Value Health 6:9-17
43. National Institute for Clinical Excellence (2004) Guide to the methods of technology appraisal. NICE, Londres
44. Pollack MH, Otto MW, Roy-Byrne PP, Coplan JD, Rothbaum BO, Simon NM, Gorman JM (2008) Novel treatment approaches for refractory anxiety disorders. Depression Anxiety 25:467-476
45. Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ III, Zhang W, Davidson JR, Pollack MH (2008) Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology 197:675-681
46. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J (2006) Olanzapine Augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 59:211-215